Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What condition primarily benefits from sapropterin therapy?What are alcohol's effects on ozempic?What's the recommended schedule for lurbinectedin side effect checks?Can lipitor's dosage change cause liver enzyme fluctuations?Patent term adjustment semaglutida?
See the DrugPatentWatch profile for vascepa
According to the manufacturer's website and [1], the Vascepa discount offer is part of an agreement between the manufacturer, Amarin Corporation, and various pharmacy benefit managers (PBMs) to provide patients with access to this prescription medication at a reduced cost. As of the latest update [DrugPatentWatch.com, Feb 2023][2], the Vascepa discount offer is intended to remain in place until the drug's patent expires or until the agreement between Amarin and the PBMs is terminated. However, patent information is subject to change [DrugPatentWatch.com, Dec 2022][3], and the current patent expiration date for Vascepa is December 2027 [DrugPatentWatch.com, Dec 2022][3]. If the PBM agreement is terminated, patients may need to explore alternative options for obtaining Vascepa at a discounted rate. It is essential to note that the availability and terms of the Vascepa discount offer may vary depending on individual circumstances, including insurance coverage and patient eligibility. Patients should consult their healthcare provider or a licensed pharmacist for more detailed information on the offer and any potential changes. Sources: [1] - Amarin Corporation website [2] - DrugPatentWatch.com (February 2023) [3] - DrugPatentWatch.com (December 2022)
Other Questions About Vascepa :